Minutes of the 170th Meeting of the National Advisory Council on Alcohol Abuse and Alcoholism

Thursday, September 4, 2025

DEPARTMENT OF HEALTH AND HUMAN SERVICES

NATIONAL INSTITUTES OF HEALTH

NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM

The National Advisory Council on Alcohol Abuse and Alcoholism (NIAAA) convened its 170th meeting at 12:02 p.m. on Thursday, September 4, 2025, in hybrid format. The Council met in closed session from 10:00 a.m. to 10:19 a.m. to review grant applications and cooperative agreements. Dr. Philippe Marmillot, Director of the Office of Extramural Activities, presided over the Council’s review session which, in accordance with the provisions of Sections 552b(C)(6), Title 5, U.S.C., and 10(d) of Public Law 92-463, excluded the public for the review, discussion, and evaluation of individual applications for Federal grant-in-aid funds. The closed session recessed at 10:19 a.m.

Council Members Present:Haiden A. Huskamp, Ph.D. David Kareken, Ph.D. Frances Rudnick Levin, M.D. Michael J. Lewis, Ph.D. Dayne Mayfield, Ph.D.

NIAAA Director and Chair: George F. Koob, Ph.D.

NIAAA Deputy Director:Patricia Powell, Ph.D.

Executive Secretary:Philippe Marmillot, Ph.D.

Senior Staff:Mark Egli, Ph.D; Ralph Hingson, Sc.D.; Katherine Jung, Ph.D.; Laura Kwako, Ph.D.; and David Lovinger, Ph.D.

Other Attendees at the Open Session:Approximately 150 people observed the meeting in person or online, including representatives from constituency groups, liaison organizations, NIAAA staff, and members of the general public.

Call to OrderDr. Koob called the open session of the Council meeting to order at 12:02 p.m. on Thursday, September 4, 2025. Council members and NIAAA senior staff introduced themselves.

Director’s ReportDr. Koob highlighted recent NIAAA activities, referring to the written Director’s Report.

Introduction. Dr. Koob updated Council members on key items discussed during an Institute/Center (IC) Directors meeting in the morning preceding the present Council meeting. Notably, the current House appropriations bill maintains the FY 2025 NIH funding level with no indication of a reorganization. A Continuing Resolution (CR) into November/December is anticipated.

Early Retirements and Departures: In addition to the early retirements and departures highlighted in the May 13, 2025, Council meeting, Dr. Koob provided an update on staff departures since then. These included Dr. Bridget Williams-Simmons, Associate Director for Basic Research and Director of the Office of Science Policy and Communications Branch, who retired early after 20 years of federal service. She provided leadership in strategic planning for NIAAA, advised the NIAAA Director on basic research and other areas, provided oversight for NIAAA’s legislative, science policy, information sharing, resource development, and outreach programs, and helped partner NIAAA with the scientific and alcohol stakeholder communities to enhance the Institute’s visibility and impact. Dr. Williams-Simmons’ office no longer exists; its function will be incorporated into a centralized NIH communication office.

Other departures include Fred Donodeo, Chief of the Communications and Public Liaison Branch, who retired after 27 years of federal service. He led the branch’s efforts in news media relations, multimedia educational content development, website management, social media, and community outreach. Dr. Tommy Gunawan, a Visiting Fellow in the Laboratory of Human Psychopharmacology, has accepted a position as a Scientist at Uniformed Services University. Dr. Andrew Kesner, Chief of the Unit of Motivation and Arousal (UMA) in the Laboratory for Integrative Neuroscience (LIN), has taken a position at Indiana University Indianapolis as a tenure-track Assistant Professor in the Department of Psychology. Dr. John Matochik, a Health Scientist Administrator in the Division of Neuroscience and Behavior (DNB) retired after 18 years of federal service. Dr. Matochik managed a grant portfolio that included research on neurobiological and cognitive/behavioral mechanisms associated with alcohol use disorder (AUD). He was the co-chair of the NIDA-NIAAA Neuroscience Working Group. Heather Olusoga, a Grants Management Specialist in the Grants Management Branch, retired after 21 years of federal service. Dr. Lenny Pommerolle, a Post-Doctoral Visiting Fellow in the Section on Fibrotic Disorders, concluded his employment to care for his family. Dr. Deidra Roach, a Medical Officer in the Treatment, Health Services and Recovery Branch, retired after 25 years of federal service. Dr. Roach oversaw grant portfolios in women’s health, co-occurring mental health/AUD, and HIV/AIDS. She co-chaired the Interagency Work Group on Drinking and Drug Use in Women and Girls and served on the Interagency Coordinating Committee on Fetal Alcohol Spectrum Disorders.

Early Retirements.The following NIAAA staff elected to retire early this year: Kimberly Benton, an Ethics Program Specialist in the Ethics and Management Branch; John Bowersox, Lead Technical Writer-Editor in the Communications and Public Liaison Branch of the Office of Science Policy and Communications; Kimberly Martin, a Technical Writer in the Communications and Public Liaison Branch, deferred retirement after 17 years of federal service; Joanna Mayo, Secretary in the Office of Science Policy and Communications, retired early after 35 years of federal service; and Amy Matush, the Branch Chief for the Ethics and Management Analysis Branch, retired early after 25 years of federal service.

Staff Departures due to Reduction in Force.The following NIAAA staff were affected by a reduction in force at NIH: Cara Anjos Breeden, a Technical Writer Editor in the Communications and Public Liaison Branch; Regina Carter, a Management Analyst in the Ethics and Management Analysis Branch; Deborah Langer, a Technical Writer Editor in the Communications and Public Liaison Branch; Katherine Masterton, a Public Affairs Specialist in the Communications and Public Liaison Branch; Colleen McDonough, a Program Specialist in the Administrative Services Branch; Teresa Ramirez, a Health Specialist in the Division of Metabolism and Health Effects; Natalia Revzina, a Health Program Specialist in the Office of the Director; Daniel Smyth, a Management Analyst in the Ethics and Management Analysis Branch; and Yesika Valdes Villalpando, a Program Specialist in the Division of Epidemiology and Prevention Research.

Reassignments Related to NIH’s Restructuring.These NIAAA staff have been reassigned to positions outside NIAAA: Aamna Bhatti is transitioning from Program Analyst within the Science Policy Branch to the NIH Office of Science Policy; Dr. Laura Brockway-Lunardi transitioned from Branch Chief within the Science Policy Branch to the NIH Office of Legislation and Policy Analysis; Dr. Beata Buzas transitioned from Scientific Review Administrator within the NIAAA Extramural Project Review Branch to the NIH Center for Scientific Review (CSR); Dr. Mamatha Garige transitioned from Scientific Review Administrator within the NIAAA Extramural Project Review Branch to CSR; Dr. Anna Ghambaryan transitioned from Scientific Review Administrator within the NIAAA Extramural Project Review Branch to CSR; Dr. Laura Manella is transitioning from Health Science Policy Analyst within the Science Policy Branch to the NIH Office of Communication and Public Liaison (OCPL); Dr. Devin Plote is transitioning from Health Science Policy Analyst within the Science Policy Branch to the NIH Office of Legislation and Policy Analysis; and Dr. Pamela Wernett is transitioning from Senior Health Science Policy Analyst within the Science Policy Branch to the OCPL.

In all, NIAAA has lost one-third of its workforce.

NIH and NIAAA Updates.Dr. Koob was invited to join a Working Group in the Office of the Director to review NIH Notices of Funding Opportunities (NOFOs), established in response to an Executive Order from the White House on Improving Oversight of Federal Grantmaking (August 7, 2025). NIH had over 800 active NOFOs on January 1, 2025, some of which were over 40 pages long, boiler-plated, and repetitive. Thus, the Working Group had the opportunity to streamline and simplify the process, driven by three overall goals: 1) Empower more investigator-driven projects; 2) Reduce overly narrow/specific NOFOs; and 3) Increase efficiency by reducing the administrative burden. To date, the Working Group has developed a plan for 1) Enhanced Parent Announcements, i.e., developing NIH-wide parent announcements to reduce the large number of IC-specific announcements and consolidating related grant mechanisms in new Parent Announcements; 2) Non-Parent Notices required to move a particular initiative/specific area forward and are not be able to be addressed by current parent announcements, e.g., a NOFO specific to alcohol; and 3) Highlighted Topics (HTs), areas of emphasized priorities. The primary writer of each HT is allocated 3,000 characters to describe the initiative; each participating IC may describe its interest in the topic within 1,000 characters.

Under the proposed new procedures, NIAAA will submit a forecast of any alcohol-specific NOFO for approval prior to writing the notice.

Budget.Under the Continuing Resolution (Public Law 119-4), NIAAA was appropriated $595.3 million for FY 2025, the same as FY 2024 enacted levels with no reductions. This funding will ensure government operations through September 30, 2025. The FY 2026 appropriation for NIH and NIAAA has not yet been finalized.

NIAAA Notices of Funding Opportunity (NOFOs):Dr. Koob announced the following NIAAA funding opportunities.

•Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33: PAR-25-158 and R34: PAR-25-159): To focus on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and (2) interventions for FASD.

•Alcohol Health Services Research (R34, PAR-25-192, and R01, PA-25-245): To support research on closing the treatment gap for individuals with alcohol use disorder (AUD), including increasing access to treatment and making AUD treatment more appealing, and reducing health disparities as a means of addressing the treatment gap.

•Alcohol Treatment, Pharmacotherapy, and Recovery Research(R01, PA-25-163 and R34, PA-25-193): To support a broad range of topics, including medications development, precision medicine, behavioral therapies, mechanisms of behavioral change, recovery, and innovative methods and technologies.

•HIV Prevention and Alcohol(R34, PAS-25-161 and R01, PAS-25-208): Applications to expand the HIV/AIDS prevention toolkit among alcohol impacted populations and associated behavioral and biological risks for HIV.

A full list of NOFOs and Notices of Special Interest (NOSIs) may be found in the NIAAA Director’s Report.

NIAAA Facts and Statistics:Dr. Aaron White, Senior Scientific Advisor to the NIAAA Director, is the lead on updating the “NIAAA Facts and Statistics” page on the NIAAA website. The updated page will include the 2024 findings from the National Survey on Drug Use and Health (NSDUH). The NIAAA website remains active; there is discussion within NIH about centralizing IC websites.

What’s Ahead:Dr. Koob announced the following upcoming events: 1) International Fetal Alcohol Spectrum Disorders (FASD) Awareness Day, on September 9, is part of FASD Awareness Month. These events, which will be promoted on NIH channels, raise awareness about the lifelong effects of FASD, and as a reminder that there is no known safe amount of alcohol consumption during pregnancy. 2) National Recovery Month in September promotes and supports new evidence-based treatment and recovery practices, the nation’s strong and proud recovery community, and the dedication of service providers and communities who make recovery possible. 3) NIDA-NIAAA Frontiers in Addiction Research Mini-Convention will be held in person on November 14, 2025, in San Diego, CA, in conjunction with the Society for Neuroscience annual meeting, Neuroscience 2025. The agenda for the Mini-Convention includes scientific sessions on Cutting-edge Multiomic Approaches for Enhanced Drug Repurposing Strategies in Substance Use Disorders, Interrogation of Large Single-Cell Data Sets to Identify New Addiction Targets, and Human iPSC-Derived Organoids and Assembloids for Brain Development, Disorders, and Diseases.

Research Highlights.Dr. Koob presented highlights of recent research publications in the alcohol field, including new research about hyperkinesia.

“Ethanol induction of FGF21 in the liver is dependent on histone acetylation and ligand activation of ChREBP by glycerol-3- phosphate” was published in the Proceedings of the National Academy of Sciences of the United States of America (2025 Jun 3;122(22):e2505263122. doi: 10.1073/pnas.2505263122. Epub 2025 May 29. PMID: 40440069) by MC Cheong, B Mackowiak, HB Kim, G Hernandez, T Nandu, K Vale, Y Zhang, LG Zacharias, TP Mathews, B Gao, WL Kraus, SA Kliewer, and DJ Mangelsdorf. Synthesis of hormone FGF21 in the liver helps to counteract the negative impact of alcohol through downstream effects in the brain and body. In this study, researchers examined how ethanol induces FGF21 expression in the liver. They found that two byproducts of alcohol metabolism, glycerol-3- phosphate (G3P) and acetyl-CoA, work in tandem to activate the carbohydrate-responsive element binding protein (ChREBP) to induce Fgf21 transcription in mice. Fgf21’s transcription could <be blocked when a histone acetyl transferase inhibitor was used. Understanding the mechanisms by which Fgf21 is activated and acts downstream may provide targets to treat AUD and reduce the negative health impact of alcohol misuse.

“Suppression of binge alcohol drinking by an inhibitory neuronal ensemble in the mouse medial orbitofrontal cortex” was published in Nature Neuroscience (2025 Aug;28(8):1741-1752. doi: 10.1038/s41593-025-01970-x. Epub 2025 Jun 10. PMID: 40495064) by P Gimenez-Gomez, T Le, M Zinter, P M'Angale, V Duran-Laforet, TG Freels, R Pavchinskiy, S Molas, DP Schafer, AR Tapper, T Thomson, and GE Martin. In this study, researchers elucidated the mechanism behind a previously noted association between activity in the medial orbitofrontal cortex (mOFC) and binge drinking. They identified a predominantly GABAergic neuronal ensemble through Targeted Recombination in Active Populations (TRAP2) that was stably activated during binge alcohol exposure, but not to exposure of water or saccharine solution. The findings support the plausibility of a neuronal “switch” underlying the overconsumption of alcohol. If a similar mechanism is shown to operate in humans with AUD, this neural ensemble may be a promising treatment target.

“Influence of real-world cue exposure and mood states on drinking: testing neurobiological models of alcohol use disorder” was published in Psychopharmacology (Berl) (2025 Aug;242(8):1727-1739. doi: 10.1007/s00213-025- 06752-8. Epub 2025 Feb 10. Erratum in: Psychopharmacology (Berl). 2025 Aug;242(8):1741. doi: 10.1007/s00213-025-06769-z. PMID: 39924613) by LR Meredith, WA Baskerville, C Lee, EN Grodin, KM Wassum, and LA Ray. Researchers evaluated daily diary data from adults with AUD for self-reported pre-drinking mood states, alcohol cue exposure, craving levels, and subsequent alcohol intake. They found that greater cue exposure was associated with higher daily drinking levels but not daily alcohol craving. However, more negative moods were associated with higher alcohol craving. Combined, they saw that as negative mood levels increased, the relationship between cue exposure and same-day drinking became stronger. These findings provide support for the negative emotionality model and incentive salience (incentive sensitization) model as determinants of alcohol craving and drinking among individuals with AUD.

“Examining the longer-term efficacy of brief, alcohol-focused personalized feedback interventions for individuals with internalizing distress: Secondary analysis of a randomized controlled trial” was published in Addiction (2025 Aug;120(8):1666-1678. doi: 10.1111/add.70044. Epub 2025 Apr 9. PMID: 40202024) by ML Piccirill, S Graupensperger, K Walukevich-Dienst, E Lehinger, KN Smith-LeCavalier, KT Foster, and ME Larimer. Researchers analyzed secondary data from a randomized controlled trial to test the moderating effect of internalizing distress (i.e., symptoms of depression, anxiety, and stress) on the efficacy of brief, alcohol personalized feedback interventions (PFIs) in college students. Baseline levels of internalizing distress were measured using the summed total of the Depression, Anxiety and Stress Scales (DASS). Drinking outcomes were measured at baseline, 3, 6, and 12 months post-PFI. Alcohol PFI reduced alcohol consumption and related consequences at 6- and 12-month follow ups regardless of baseline DASS score. Results also showed that single-component PFIs were more effective in reducing alcohol-related consequences at 6 months compared to multi-component PFIs.

Discussion:Dr. Lewis inquired if the studies described in the Research Highlights were all supported, at least in part, by NIAAA; Dr. Koob confirmed this to be the case. Dr. Lovinger noted that the FGF21 study was partially supported by the NIAAA intramural program. At Dr. Lewis’ request, Dr. Koob asked Dr. Marmillot to send a copy of the Director’s Report slides to Council members.

Council DiscussionDr. Koob invited Council members to ask any questions they may have about the status of NIAAA following the transition to a new administration. He opened the discussion by noting that staff in NIAAA’s Grants and Contracts Office have been working diligently to get all grants out before the end of FY 2025 (September 30, 2025). Currently, no NIAAA grants have been terminated, although some have been withdrawn as noted by Dr. Marmillot. Dr. Koob explained that grants that were previously terminated have been reinstated; in some cases, reinstatement occurred following negotiation with the grantee to ensure that grant language aligned with NIH priorities. Thus, despite a long delay, NIAAA’s portfolio will be funded.

Dr. Lewis inquired about policies that Council members should adopt regarding speaking with members of the press about NIAAA’s status and grant funding. Dr. Koob stated that the public should have access to information about NIAAA-funded research because it is public tax dollars that support NIAAA activities. Dr. Powell noted that public-facing information about NIAAA grants may be found on the NIH RePORTER site; Council members can refer reporters to this site.

Noting Dr. Koob’s comment that NIAAA has lost about one-third of its staff, Dr. Kareken asked Dr. Koob if he anticipated that this understaffing would lead to long-term difficulties or if the reorganization and centralization of functions within NIH would ease the administrative management of the Institute. Dr. Koob responded that he is hopeful that the consolidation of functions will ease the bureaucratic burden and compensate for the loss of individual staff. For example, press inquiries will now be submitted to a central press office and only referred to NIAAA when needed. At the same time, NIAAA is hoping that the current hiring freeze may be lifted soon so that staffing gaps may be addressed.

Dr. Mayfield commented that the concept of Highlighted Topics (HTs) will be a bonus for investigators who will no longer have to navigate hundreds of funding notices. Dr. Koob concurred, noting that the HTs allow investigators to spend more time on research and less time navigating the search for grants. He also mentioned an anticipated NIH-wide change, the elimination of paylines for grant funding. NIAAA has never used a payline, instead reporting on success rates of applicants. By not utilizing a payline, NIAAA has had greater flexibility to integrate grant application review scores from CSR with an evaluation of how well each grant aligns with NIAAA’s strategic research goals.

Dr. Huskamp requested clarification of the timeline for implementing the HTs. Dr. Koob responded that more guidance will be forthcoming from the Office of Extramural Research (OER) in the Office of the Director (OD). Dr. Powell explained that NIH is still working out how broad the scope of HTs should be, noting that they should lead to collaborative cross-NIH research. The HTs are currently in beta testing. Dr. Koob expanded on the current status of the HTs, pointing out that NIH has not yet addressed where to attach monies to HTs nor how to track responses. From his perspective, it will still be possible for NIAAA to issue a Request for Applications (RFA) and officially attach a budget to it. However, the HTs will allow investigators to understand IC priorities and will save research institutions time and money spent searching for funding opportunities. Dr. Huskamp inquired if there would be a mechanism to address cross-cutting topics, such as comorbidities, across ICs. Dr. Koob responded affirmatively. Dr. Jung commented that she was proud of a study funded by the Division of Metabolism and Health Effects on comorbidity between alcohol use and alcohol-related liver disease. Dr. Levin identified the need for more comorbidity research on alcohol and psychiatric conditions, an area she believes is underfunded by NIAAA. Dr. Koob commented that at meetings of the Research Society on Alcohol (RSA) and The College on Problems of Drug Dependence (CPPD), many people asked why NIAAA was not conducting more comorbidity studies, noting that they are difficult to implement. Dr. Powell added that more research on comorbidities associated with prenatal exposure to alcohol is needed, as some consequences emerge only in middle age. She noted that comorbidity studies often don’t do well in the review process, but reiterated that NIAAA can still fund them if they align with the Institute’s priorities. Dr. Kwako commented that the Division of Treatment and Recovery would welcome an increased priority for comorbidity research, not only on etiology and treatment but also on service delivery, which is often overlooked. Dr. Huskamp remarked that the payment and funding streams are often different for different conditions. Dr. Koob encouraged Council members to bring significant gaps in alcohol-related research, such as comorbidities, to his or Dr. Powell’s attention. For example, he noted that NIAAA has not adequately addressed alcohol use in the criminal justice system and has funded little research about alcohol’s impact on the pancreas, heart, and other body organs. Alcohol and aging is another area of research ripe for expansion, as Baby Boomers are the only population segment that is increasing alcohol consumption.

Dr. Lewis asked about the functioning of Council and study sections in the future. Dr. Koob responded that Dr. Marmillot has had to resubmit proposed 2026 and 2027 Council slates; there is still no resolution, but NIH Director Jay Bhattacharya, M.D., Ph.D., is working on this issue. He noted that current Council members will remain in their roles until a new Council slate is approved. Dr. Koob also noted that all study sections are now at CSR. Dr. Marmillot commented that NIAAA has three scientific review officers who have been reassigned to CSR and can represent NIAAA’s interests. Dr. Koob encouraged Council members to report any review issues to NIAAA so that the Institute can provide input to CSR. He also noted that one of Dr. Bhattarcharya’s priorities is innovative research, which often gets lost in review, in addition to chronic disease, longevity, reproducibility, replicability, and gold standard science; Dr. Bhattacharya has provided a more detailed list, including autism and HIV research, to the ICs. Dr. Koob encouraged Council members to share their insights into what constitutes innovative research.

Dr. Kareken commented that many of his colleagues are concerned about recent NIH guidance on minimizing the use of animals. He asked how Dr. Koob expects that guidance to be implemented. Dr. Koob responded that ICs are discouraged from putting animal model development projects into NOFOs or HTs. For example, research on models of craving should incorporate both human and laboratory approaches. Alternative methods, when available, should be included in any research goal that utilizes animals and should be run in parallel; doing so can save on animal research, as well as time and money. There is no ban on animal research, but proposals that focus on animal studies should consider a translational component to human biology. Dr. Kareken clarified that applications using an animal model would not automatically be disqualified from consideration; Dr. Koob affirmed that there are currently no restrictions on grant applications of any kind. Dr. Egli expanded on Dr. Koob’s remarks, reflecting on his experiences serving on some NIH committees considering the use of animal research. He noted that everyone involved in those discussions acknowledges that new alternative methods (NAMS) are highly useful in some settings and are still under development in others. The idea is to integrate animal studies where needed because some invasive mechanistic work cannot be done in humans. But animal studies should intersect with human biology, either through NAMs or parallel clinical studies. The bottom line is that NIH will no longer be developing and issuing funding opportunities that say no clinical studies allowed. This policy is being promoted to accelerate the application of research findings to the population. Dr. Koob stated that perspectives on animal research will be evolving as the Brain Research Through Advancing Innovative Neurotechnologies® (BRAIN) Initiative starts up again. He noted that a research gap in the neuroscience field is the clinical use of transcranial magnetic stimulation (TMS) to treat AUD, despite a dearth of preclinical studies to understand what happens in the brain when TMS is applied. Dr. Lewis commented that anti-animal research advocates sometimes promote outlandish theories that throw doubt on the validity of good animal-based studies. Dr. Koob responded that there are well-established and proven animal models in the addiction field.

Dr. Marmillot concluded the discussion by noting that the HT webpage is live on the NIH Grants & Funding page with seven topics highlighted. He encouraged Council members to review the site when searching for a fit for potential research studies.

Consideration of the NCAA and CRAN Meeting Minutes, Council SOP, and Future MeetingsThe May 13, 2025, Council meeting minutes, the May 14, 2025, Collaborative Research on NIH Addiction (CRAN) meeting minutes, and the Council Standard Operating Procedures (SOP) were approved unanimously.

Dr. Koob reviewed a slide titled “New Resource for HT Topics” developed by Jennifer Webster-Cyriaque, D.D.S., Ph.D., Acting Director of the National Institute of Dental and Craniofacial Research, to provide further guidance on HTs in response to Dr. Huskamp’s earlier questions. The slide highlights how HTs can be a resource to inform the research community about NIH areas of scientific interest by: 1) encouraging investigator-initiated applications in those topic areas; 2) potentially including new or emerging areas; 3) expiring after one year; NIH may extend; and 4) helping reduce NIH's use of funding opportunities by highlighting a topic instead, as appropriate. The slide also lists benefits for the research community: 1) reducing the effort to search and apply for funding opportunities; 2) applying through one of the NIH parent announcements or other broad NIH opportunities at grants.gov; 3) searching topics by keyword and filtering by participating NIH institutes, centers, or offices; and 4) checking back often for new topics and web page features.

Dr. Marmillot announced future Council meeting dates. In 2026, Council will meet on February 5, May 5, and September 17; the 2026 CRAN meeting will be on May 6. In 2027, Council will meet on February 4, May 11, and September 16; the 2027 CRAN meeting will be on May 12.

AdjournmentDr. Koob adjourned the meeting at 1:40 p.m.

CERTIFICATION

I hereby certify that, to the best of my knowledge, the foregoing minutes are accurate and complete.

s/s

George F. Koob, Ph.D.

Director

National Institute on Alcohol Abuse and Alcoholism

and

Chairperson

National Advisory Council on Alcohol Abuse and Alcoholism

s/s

Philippe Marmillot, Ph.D.

Executive Secretary

National Advisory Council on Alcohol Abuse and Alcoholism